Conference Details - Overview

View all Conferences

Continuing Education Information

Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is approved for AMA PRA Category 1 Credit™

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Ninth International Congress on Genitourinary Malignancies

Renaissance Mayflower Hotel
Washington, DC
July 16-18, 2009

Conference Overview

Oncology CME-Certified Congress

The Ninth International Congress on Genitourinary Malignancies will provide a comprehensive review of current therapeutic standards for all aspects of the treatment of kidney, bladder, and prostate cancers, including clinical and molecular disease characterization, prevention, prognostication, multimodality management of disease, and novel therapeutic agents. Interactive panel discussions and case-based scenarios will provide context for the interpretation of presented data from clinical trials. Faculty recommendations and interactive tumor board–style discussion will aid in transitioning treatment standards to individualized care in the practice setting. Participants will be able to integrate the latest advances in the treatment of genitourinary malignancies into their daily practice as well as discuss future directions in research and clinical trials.

This educational program is directed toward medical, surgical, and radiation oncologists; urologists; internal medicine and primary care physicians; and basic research investigators. Fellows, oncology nurses, physician assistants, and pharmacists interested in the treatment and management of patients with genitourinary malignancies are also invited to attend.

At the conclusion of this congress, you should be able to:

Bladder Cancer

  • Practice state-of-the-art management of bladder cancer, including treatment standards for the surgical and clinical management of nonmuscle and muscle-invasive disease
  • Review options in adjuvant and neoadjuvant therapy
  • Compare chemotherapy regimens for muscle-invasive and advanced disease

Prostate Cancer

  • Summarize the molecular elements of prostate cancer pathobiology and the significance of biomarkers in determining risk
  • Compare the roles of active surveillance and intervention treatment strategies in early-stage disease
  • Integrate multimodality treatment, including hormonal therapy, chemotherapy, radiation therapy, and surgery, into the treatment of patients with prostate cancer, including those with hormone-refractory and high-risk localized diseases
  • Evaluate state-of-the-art care and future directions of therapy, including surgical advances, treatment options for chemotherapy-refractory disease, and biomarkers for selection, for patients with prostate cancer
  • Assess the efficacy and safety of immunotherapy for prostate cancer

Renal Cell Carcinoma

  • Review the basic biology, genetics, and natural history of renal cell carcinoma
  • Differentiate patient prognostic groups based on pretreatment risk features
  • Incorporate current standards into the surgical and clinical management of patients with small/localized, invasive, and metastatic kidney cancers
  • Manage patients with advanced/metastatic clear cell and non–clear cell renal cell carcinoma by incorporating current algorithms into the treatment of those having favorable/intermediate-risk features, poor-risk features, or recurrent disease
  • Asses the efficacy and safety of immunotherapy for renal cell carcinoma
  • Discuss the optimal administration of targeted biologic agents and the definition of treatment failure in patients with refractory metastatic disease
  • Assess the role of biomarkers in devising treatment strategies for patients with advanced disease
  • Describe unique pathogenic elements and the natural history of non–clear cell renal cell carcinoma

All Tumor Types

  • Evaluate the potential impact of novel biologic and chemotherapeutic agents being investigated for use in patients with bladder, kidney, and prostate cancers
  • Improve the quality of life for patients with bladder, prostate, and kidney cancers by effectively managing the side effects of both disease and treatment
  • Refer appropriate patients to promising clinical trials

Educational Grants

An educational grant for this activity was provided by:


  1. AstraZeneca
  2. Bayer HealthCare Pharmaceuticals/
    Onyx Pharmaceuticals, Inc.
  3. Genentech BioOncology
  4. sanofi-aventis U.S.